AYA.AX Artrya Limited ASX A$3.65 pre-market 05 Feb 2026: U.S. expansion insight

AYA.AX stock trades at A$3.65 pre-market on 05 Feb 2026 as Artrya Limited (ASX) highlights U.S. growth in its Q2 discussion. The price sits near the 200-day average of A$2.28 and below the 50-day average of A$4.00, signalling recent consolidation. Volume is modest at 286,198 shares versus a 30-day average of 787,407. Investors watching AI healthcare plays should weigh the U.S. rollout and upcoming earnings on 24 Feb 2026 against current valuation metrics and cash runway.

AYA.AX stock: Quick trading snapshot

Artrya Limited (AYA.AX) is priced at A$3.65 pre-market with day range A$3.51–A$3.71 and a one-day gain of 2.53%. Market capitalisation is A$413.62m with 113,320,000 shares outstanding. The stock sits below its 50-day average of A$4.00 and above its 200-day average of A$2.28, which shows mixed short and medium-term momentum.

AYA.AX stock: Recent news and catalysts

Artrya’s Q2 2026 earnings call stressed U.S. commercial expansion as the primary growth driver, a near-term catalyst for adoption of the Salix AI platform. The company flagged sales and pilot activity in U.S. health systems, which investors will watch ahead of the earnings announcement on 24 Feb 2026. For source detail, see the Q2 call transcript on Investing.com and the MarketWatch quote page for live pricing MarketWatch.

AYA.AX stock: Fundamentals and valuation

Artrya reports EPS of -0.18 and a trailing PE of -20.28, reflecting current losses as it scales commercial operations. Cash per share is A$0.11 and book value per share is A$0.21, while the current ratio is 8.27, indicating short-term liquidity. Valuation ratios such as price-to-sales (14,772.07) and price-to-book (17.67) are extreme versus healthcare peers, driven by low revenue per share and high R&D intensity.

AYA.AX stock: Technicals and market signals

Momentum indicators show strength and short-term overbought conditions: RSI is 70.89 and MACD histogram is positive at 0.09. The 50/200-day trend mix supports a higher timeframe uptrend, with ATR at 0.32 signalling moderate intraday volatility. Trading volume is below average today, with relative volume at 0.36, so price moves may not yet have strong conviction.

AYA.AX stock: Meyka AI grade and model forecast

Meyka AI rates AYA.AX with a score out of 100: 59.21 (Grade C+, suggestion HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, analyst consensus, and forecast data. Meyka AI’s forecast model projects A$7.90 in one year and A$5.83 for a quarterly horizon. From the current price of A$3.65, the one-year projection implies an upside of 116.44%. Forecasts are model-based projections and not guarantees.

AYA.AX stock: Risks and opportunities for AI healthcare investors

Opportunity: Artrya’s Salix platform targets automated coronary disease detection, which can scale in U.S. hospitals and raise recurring revenue over time. Risk: current revenue per share is near zero and margin metrics remain negative, making the stock dependent on successful U.S. commercialisation. Investors should track pilot conversions, regulatory milestones, and the 24 Feb 2026 earnings update.

Final Thoughts

Key takeaways for AYA.AX stock investors: Artrya is trading at A$3.65 pre-market on 05 Feb 2026 while management emphasises U.S. expansion as the near-term growth engine. Financials show negative EPS (-0.18) and stretched valuation ratios, but liquidity metrics such as a current ratio of 8.27 reduce short-term solvency risk. Meyka AI’s model projects A$7.90 in one year, implying a 116.44% upside from today’s price. The company faces execution risk converting pilots into revenue, and sector comparisons show healthcare peers trade at much lower price-to-book ratios. Use the upcoming 24 Feb earnings report to reassess adoption metrics and revenue guidance. Meyka AI, the AI-powered market analysis platform, flags AYA.AX as a speculative AI-healthcare growth stock where upside depends on U.S. commercial traction. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.